BLOG

global genes

X4 Pharmaceuticals’ Phase 2 WHIM Treatment Data Published in the Journal Blood

X4 Pharmaceuticals said that comprehensive data from its mid-stage trial of mavorixafor for the treatment of adult patients with the rare genetic syndrome WHIM was published in Blood, the official journal of the American Society of Hematology.